The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
ACR Image Competition 2024 Results, Part 3
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from Latin America and the Caribbean. Diagnosing Juvenile PsA A 13-year-old boy presented with a seven-year history of…
FDA Approves Bimekizumab-bkzx (Bimzelx) for 3 New Rheumatic Indications
The FDA has approved bimekizumab-bkzx for the treatment of adults with psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Prevalence of Fibromyalgia & Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large U.S. Registry
According to a new study, fibromyalgia prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat-to-target goals.
What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients with Psoriasis?
Objective We aimed to identify clinical and demographic features associated with the interval between the appearance of psoriasis and the onset of psoriatic arthritis (PsA). Methods We identified patients with psoriasis and PsA diagnoses from our tertiary care psoriatic disease biorepository: a longitudinal, real-world database including clinical information and patient-reported outcomes. We used a multivariable,…
Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
Diagnosing Skin Disease in Patients with Dark Skin
Many rheumatologists may not be trained to properly identify the signs of skin disease in patients with dark skin, but in this ACR Convergence session, experts provide practical guidance for diagnosis.
Should We Manage Men & Women Differently?
Experts address how sex differences affect the clinical presentation, diagnosis, response to therapy and experience of illness for patients with PsA.
Advancements in Imaging
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
The Management of Psoriatic Arthritis: A Review
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 17
- Next Page »